Prior notification of a concentration (Case M.11445 – CARLYLE / GTCR / RESONETICS) – Candidate case for simplified procedure
Date: 2024-03-19
Institutions: Directorate-General for Competition, European Commission
Subjects: economic concentration, health technology, investment company, medical device, merger control








C_202402259EN.000101.fmx.xml












Official Journal of the European Union


EN
Series C













C/2024/2259


19.3.2024






Prior notification of a concentration
(Case M.11445 – CARLYLE / GTCR / RESONETICS)
Candidate case for simplified procedure
(Text with EEA relevance)
(C/2024/2259)


1.   
On 12 March 2024, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:






—


The Carlyle Group Inc. (‘Carlyle’, USA),










—


GTCR LLC (‘GTCR’, USA),










—


Regatta Laser Holdings, LLC (‘Resonetics HoldCo’, USA), ultimately controlled by GTCR. Regatta Laser Holdings, LLC is the holding company of Resonetics LLC and Resonetics Swiss Holdings GmbH, together with their respective subsidiaries (‘Resonetics’, USA).




Carlyle and GTCR will acquire within the meaning of Articles 3(1)(b) and 3(4) of the Merger Regulation joint control of Resonetics.
The concentration is accomplished by contractual means.


2.   
The business activities of the undertakings concerned are the following:






—


Carlyle is a global alternative asset manager, which manages funds that invest globally across three investment disciplines: (i) Global Private Equity (including corporate private equity, real estate and natural resources funds); (ii) Global Credit (including liquid credit, illiquid credit and real assets credit); and (iii) Investment Solutions (private equity fund of funds program, which include primary fund, secondary and related co-investment activities),










—


GTCR is a private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare, Technology, Media & Telecommunications and Business Services industries,










—


Resonetics is an independent medical technology contract development and manufacturing organisation (CDMO) specialising in complex micro manufacturing of highly engineered components, implants, subassemblies, and finished devices.






3.   
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
Pursuant to the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004 on the control of concentrations between undertakings (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.


4.   
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.11445 – CARLYLE / GTCR / RESONETICS
Observations can be sent to the Commission by email or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Postal address:





European Commission




Directorate-General for Competition




Merger Registry




1049 Bruxelles/Brussel




BELGIQUE/BELGIË







(1)  
            OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2)  
            OJ C 160, 5.5.2023, p. 1.


ELI: http://data.europa.eu/eli/C/2024/2259/oj
ISSN 1977-091X (electronic edition)